Ponatinib

Drug Profile

Ponatinib

Alternative Names: AP-24534; AP24534 HCl; AP24534 hydrochloride; AP24534-HCL; Iclusig; Ponatinib hydrochloride

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ARIAD Pharmaceuticals
  • Developer ARIAD Pharmaceuticals; Dana-Farber Cancer Institute; Massachusetts General Hospital; Mayo Clinic; National Cancer Institute (USA); Otsuka Pharmaceutical; University of Birmingham; University of Colorado at Denver
  • Class Antineoplastics; Benzamides; Imidazoles; Piperazines; Pyridazines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Fibroblast growth factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia; Acute lymphoblastic leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Acute lymphoblastic leukaemia; Chronic myeloid leukaemia
  • Phase II Acute myeloid leukaemia; Biliary cancer; Gastrointestinal stromal tumours; Lung cancer; Squamous cell cancer; Thyroid cancer
  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia in USA (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO, Tablet)
  • 15 Sep 2017 Ariad Pharmaceuticals and University of Birmingham completes a phase I/II trial in Chronic myeloid leukaemia (Combination therapy, In adolescents, In adults) in United Kingdom (PO) (EudraCT2012-005629-65)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top